

S/N 09/125,751

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FODSTAD et al.	Examiner:	S. Ungar
Serial No.:	09/125,751	Group Art Unit:	1642
Filed:	October 30, 1998	Docket No.:	7885.55USWO
Title:	METHOD OF KILLING TARGET CELLS IN HARVESTED CELL POPULATIONS WITH ONE OR MORE IMMUNOTOXINS		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 371504194 US
Date of Deposit: October 5, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop AMENDMENT, P.O. Box 1450, Alexandria, VA 22313-1450.

By: _____
Name: DAVID ORTIZ

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

10/08/2004 SNAJARRO 00000089 09125751

02 FC:1806

180.00 0P

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300

Dated: October 5, 2004

By: 
John J. Gresens
Reg. No. 33,112

JJG/nel

23552

PATENT TRADEMARK OFFICE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		"Making the most of mucin: a novel target for tumor immunotherapy", Barratt-Boyes SM, Cancer Immunol Immunother. 1996 Nov; 43(3): 142-51.					
		"The Epithelial Glycoprotein 2 (EGP-2) Promoter-driven Epithelial-specific Expression of EGP-2 in Transgenic Mice: A New Model to Study Carcinoma-directed Immunotherapy:", McLaughlin et al., Cancer Research 61, 4105-4111, May 15, 2001.					
		"Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy", Winthrop et al., Clinical Cancer Research, Vol. 9, 3845s-3853s, September 1, 2003 (Suppl.).					
		"Kinetics of Uptake and Degradation of an Abrin Immunotoxin by Melanoma Cells and Studies of the Rates of Cellular Intoxication", Godal et al., Int. J. Cancer: 42, 400-404 (1988).					
		"Studies on the Mechanism of Action of Abrin-9.2.27 Immunotoxin in Human Melanoma Cell Lines", Godal et al., Cancer Research 47, 6243-6247, December 1, 1987.					
		"Systematic Immunotoxin Treatment Inhibits Formation of Human Breast Cancer Metastasis and Tumor Growth in Nude Rats", Engebraaten et al., Int. J. Cancer: 88, 970-976 (2000).					
		"A Murine cDNA Encodes a Pan-Epithelial Glycoprotein that is also Expressed on Plasma Cells", Bergsagel et al., The Journal of Immunology, Vol. 148, 590-596, No. 2, January 15, 1992.					
		"Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2", Szala et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 3542-3546, May 1990 Biochemistry.					
		"Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", Strnad et al., Cancer Research 49, 314-317, January 15, 1989.					
		Appendix 3-6, "Monoklonaler Antikörper BM7" and Appendix 3-7, "Monoklonaler Antikörper BM2", Brummend et al., Cancer Research, 1994, 54: 4162-4168					
		"Pharmacokinetics and Scintigraphy of Indium-111-DTPA-MOC-31 in Small-Cell Lung Carcinoma", Kosterink et al., The Journal of Nuclear Medicine- Vol. 36, No. 12, December 1995.					
		"Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas? A phase I study in patients with advanced mammary, lung, colorectal or prostate carcinoma", Aamdal et al., pp. 1-24.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	